On February 28, at the media communication meeting about the adenovirus vector new crown vaccine hosted by the Chinese Medical Association, Yu Xuefeng, chairman of Cansino Biotech Co., Ltd., who cooperated with Chen Wei’s team to develop an adenovirus vector new crown vaccine, introduced that from According to the results of phase I and II clinical studies, the main common adverse reactions after vaccination include local redness, swelling, induration, pain, itching, headache, fatigue, fever, etc., which are all normal inflammatory reactions produced by cytokines, which will soon return to normal .
In the clinical trials of the adenovirus vector new crown vaccine, no serious adverse reactions related to the vaccine occurred.
Starting from the Phase II clinical trial, there is no ceiling on the age of the subjects. The oldest vaccinator for the Phase II clinical trial is 84 years old. In the global data of the Phase III clinical trial, the elderly over 60 years old are entered The proportion of participants is close to 10%.
(Reporter Wen Mengxin produced Le Xiaomin)
Editor in charge: [Wang Sishuo]